IFM launches subsidiary for cGAS, STING inhibitors

IFM Therapeutics LLC (Boston, Mass.) launched IFM Due Inc., a subsidiary that intends to develop inhibitors of cGAS and STING to treat autoimmune and inflammatory diseases. The subsidiary also named immunologist Andrea Ablasser, a professor at the École Polytechnique Fédérale de Lausanne, as its founding scientist.

The subsidiary is the second that IFM Therapeutics has launched since it was established

Read the full 590 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE